This is a demo store. No orders will be fulfilled.
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
06 Nov 2019  |  North America  |  Mega Trends
Growth Opportunities in Human Microbiome Market, Forecast to 2023
Strategic Collaborations and Stakeholder Awareness Along with Clear Paths to Commercialization will Play a Key Role for Success in the Human Microbiome Market
Interest in the microbiome as a science and industry has exploded over the past decade. Innovations are happening across 3 significant categories for human health benefits: microbiome-based therapeutics, over-the-counter (OTC) dietary supplements, and self-diagnostics/screening. The OTC market is the largest because of the lack of precise regulatio...
$4,950.00 -
25 Apr 2019  |  North America  |  Mega Trends
Growth Opportunities in Global Vaccines Market, Forecast to 2024
Increased Investment in Adult Immunization and Improved Mammalian Cell-culture Expression Systems will Drive Growth and Profitability
The report provides an overview of the global vaccine market estimating the market size broken down by different segments. Vaccines, though a sub-set of biologics, have a completely different dynamic. Not only are they largely designed for a healthy cohort but are also exponentially influenced by government actions and policies. While old generatio...
$4,950.00 -
20 Mar 2019  |  North America  |  Mega Trends
Growth Opportunities in the North American Clinical Laboratory Services Market, Forecast to 2022
Laboratories Seek Alternate Revenue Streams to Combat Reimbursement Pressure
Clinical laboratory services represent one of the highest healthcare expenditures in North America, yet the United States and Canada represent different scenarios in the way clinical services are rendered. The market for clinical lab services in Canada was an estimated $10.33 billion in 2017 whereas in the United States it was an estimated $78.33 b...
$4,950.00 -
14 Jan 2019  |  North America  |  Mega Trends
Growth Opportunities in the Global qPCR and dPCR Market, Forecast to 2023
Novel Applications in Oncology and Applied Sciences, Growing Research and Diagnostic Use in Developing Regions, and Automated Modular Workflows to Drive Growth
Overview: PCR continues to be the gold standard for nucleic acid amplification by combining accuracy and efficacy that users across areas such as research, pharma & biotech, diagnostics as well as applied sciences depend upon. Such widespread usage continues to drive the industry, even protecting it to some extent from overall economic/market fluct...
$4,950.00 -
12 Dec 2018  |  North America  |  Mega Trends
Growth Opportunities in Functional Consumables Aftermarket, Forecast to 2023
Innovation-as-a-service Business Model will Accelerate Growth in the Molecular Diagnostic Subsegment
Rapid technological turnaround has become a norm in the life science and in-vitro diagnostic industry. Extrinsic factors such as lack of skilled labor to operate the instrumentation as well as functional factors like demand for very high precision and reproducibility of results are driving this technological evolution. As the instrument efficiency ...
$4,950.00 -
24 Oct 2018  |  North America  |  Mega Trends
Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025
A Robust Product Pipeline Creating Opportunities for Ground-breaking Combination Therapies is Set to Revolutionize the Global Cell Therapy Market
The global pharmaceuticals industry is continuously evolving to meet the requirements of a changing disease landscape. With the increasing prevalence of chronic infectious diseases and cancer, market needs are shifting from traditional small molecules to novel large molecule therapies, with cell therapies dominating the space. This study presents a...
$4,950.00 -
06 Feb 2018  |  Global  |  Mega Trends
Growth Opportunities in Clinical Trial Data Management and eClinical Solutions Market, Forecast to 2020
Digitization Presents Opportunities for Unified Cloud-based Platform Solutions to Optimize Clinical Trial Workflows
The global clinical trial IT market is expected to grow from $2.63 billion in 2016 to $4.29 billion in 2020 at a compound annual growth rate (CAGR) of more than 13.0%. North America will continue to hold the largest market share (by revenue) in 2017, followed by Europe. Increasing clinical trial activities in the emerging Asia-Pacific markets and r...
$4,950.00 -
10 Jan 2018  |  Asia Pacific  |  Mega Trends
APAC Biosimilar Market, Forecast 2025
Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth
Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Ko...
$4,950.00